Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials

Xiaoming Jia, Payal Kohli, Salim S. Virani

Research output: Contribution to journalReview articlepeer-review

26 Citations (Scopus)


Purpose of Review: Omega-3 fatty acids (ω-3 FA) are among the most well-recognized health supplements but their cardiovascular benefits have long been controversial owing to inconsistent results from previous cardiovascular outcomes trials (CVOT). In this article, we provide a short review of existing literature followed by recent randomized clinical trial data, with a discussion of the potential clinical implications of these new findings. Recent Findings: Data from the randomized, controlled trial REDUCE-IT, when viewed within the context of other recently published trials ASCEND and VITAL, add to a growing body of evidence on the use of ω-3 FA therapies in the treatment of atherosclerotic cardiovascular disease (ASCVD). Summary: Given the different formulations, dosages, and patient populations studied, CVOTs of ω-3 FA have provided valuable insight into the use of these agents in cardioprotection. Current data suggest that higher dosages of pure eicosapentaenoic acid ω-3 FA formulations provide additional benefit in reduction of ASCVD events.

Original languageEnglish
Article number1
JournalCurrent Atherosclerosis Reports
Issue number1
Publication statusPublished - 1 Jan 2019
Externally publishedYes


  • Cardiovascular outcomes
  • Docosahexaenoic acid
  • Eicosapentaenoic acid
  • Icosapent ethyl
  • Lipids
  • Omega-3 fatty acid


Dive into the research topics of 'Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials'. Together they form a unique fingerprint.

Cite this